How to Set Up Marine Biotechnology Company in Indonesia: Foreign Investor Guide

Key takeaways

• KBLI 72104 covers systematic biotechnology R&D, including industrial and environmental biotechnology, but it expressly separates medical biotechnology and does not automatically capture every fisheries or marine-science project.
• KBLI 72105 expressly includes R&D in fisheries and marine science, so the research objective—not merely the use of marine organisms—must drive classification.
• A PT PMA, NIB, and risk-based business licence do not replace research, immigration, ethics, sample-access, protected-species, quarantine, material-transfer, or biosafety controls that may attach to a project.
• The current general PMA framework uses an investment plan above IDR 10 billion per five-digit KBLI per project location, excluding land and buildings, and minimum issued and paid-up capital of IDR 2.5 billion per PT PMA, subject to stated exceptions.
• Budget the laboratory and compliance evidence separately from incorporation: premises, containment, waste handling, sample traceability, specialist personnel, product testing, and field permissions usually determine launch readiness.

Define the commercial endpoint before forming the company

The correct setup depends on the first invoice and the first regulated output. A company conducting discovery research on marine microbes is different from a laboratory selling analytical reports, a hatchery commercializing improved broodstock, or a factory producing carrageenan, enzymes, supplements, cosmetics, diagnostics, or pharmaceuticals. “Marine biotechnology” describes a technology domain; it is not a single legal permission.

Prepare a two-page scope memo before selecting a name, premises, or KBLI. It should state the research question, organisms or derivatives, source of every sample, collection locations, laboratory manipulations, whether genetic modification is involved, who owns the material and resulting IP, which services will be invoiced, whether material crosses an Indonesian border, and the first product intended for sale. The memo becomes the common input for the deed, OSS project data, lease due diligence, collaboration agreement, material transfer agreement, and product roadmap.

Treat a pilot sale as commercialization, not as a harmless extension of research. If the commercial endpoint is cultured fish, seed, or broodstock, the company should separately test the commercial hatchery licensing for biotech outputs before moving material from experimental containment into production.

Choose KBLI by research purpose and revenue

As checked on August 24, 2026, Indonesia is implementing KBLI 2025. The official OSS entry for KBLI 72104 covers systematic biotechnology R&D, including environmental biotechnology, industrial biotechnology, and uses not involving genetic modification. It excludes nanotechnology and medical biotechnology. That makes 72104 a strong candidate for platform research, bioprocess discovery, marine microbial applications, bioremediation, and industrial enzyme research when those descriptions match the actual work.

However, the OSS entry for KBLI 72105 expressly includes systematic R&D in fisheries and marine science, as well as agricultural biotechnology. A project centered on fish genetics, aquaculture health, marine ecology applied to fisheries, or aquatic breeding may therefore point to 72105 even when biotechnology tools are used. Medical or health applications, including medical biotechnology, point instead toward KBLI 72103 and can bring clinical, preclinical, ethics, and product-specific approvals.

Use a revenue test to prevent overreach. A company that primarily develops its own knowledge or technology fits the R&D family more naturally. A company that routinely accepts customer samples and sells test results should assess the technical-testing classifications, including KBLI 71204 or 71209 as relevant. A company making an ingredient or finished good needs the matching cultivation or manufacturing code. Multiple codes may be justified, but each creates a separate scope to substantiate and may affect the investment calculation, premises, licences, reporting, and inspections.

Build the PT PMA and investment case

For a foreign-owned operating company, the normal vehicle is a PT PMA. Confirm the selected activities against the prevailing investment restrictions and sector conditions before fixing the cap table; apparent eligibility for one research code does not prove that a later manufacturing, cultivation, or health activity is equally open. The deed’s objects and purposes, OSS KBLI entries, project locations, and actual contracts should describe the same business.

Under the current BKPM Regulation 5 of 2025 , a PT PMA is generally categorized as a large business. Its total investment generally must exceed IDR 10 billion, excluding land and buildings, per five-digit KBLI per project location, while minimum issued and paid-up capital is IDR 2.5 billion per company. The regulation contains activity-specific calculation rules and exceptions, so a multi-code, multi-location laboratory group needs a project-by-project calculation rather than one headline number.

These numbers are capital and investment commitments, not incorporation fees. The paid-up capital must be supportable through corporate and banking evidence, while the investment plan should reconcile to laboratory equipment, fit-out, vehicles, intangible development costs where acceptable, and other project assets. A nominal capital figure, inflated equipment list, or unrelated group expenditure creates avoidable problems in banking, LKPM reporting, and later licence verification.

The corporate sequence normally covers shareholders, directors and commissioner, company name, Indonesian address, deed, Ministry of Law approval, tax registration, bank arrangements, beneficial-ownership data, and OSS submission for the NIB and risk-based licence. For coordinated deed, KBLI, project, and evidence work, use research-led PT PMA implementation support only after the research scope and sample route are concrete enough to review.

Control samples, fieldwork, and foreign researchers

Create a material register before acquisition. For every organism, tissue, extract, environmental sample, sequence, strain, or derivative, record taxonomy, source, collection coordinates where relevant, provider, ownership, conservation status, intended tests, storage, transformations, destination, and disposal. Separate purchased reference material from newly collected Indonesian material; separate non-protected species from protected or CITES-listed species; and separate physical export from domestic analysis or digital sequence use.

A PT PMA licence does not create a right to collect in the sea. Location, vessel, conservation-area, fisheries, protected-species, customary or local access, and research permissions may apply according to where and how fieldwork occurs. KKP’s current service reporting identifies SIPJI as the written permit for utilization of a protected fish species and SAJI documents for movement; the applicable route must be confirmed against the actual species and use. Research inside a conservation area can also attract entry and activity controls.

International transfer requires an additional gate. BRIN describes a material transfer agreement as a required control for transferring Indonesian biodiversity, local specimens, or research material, with terms governing permitted use, ownership, publication, intellectual property, onward transfer, and benefit. Indonesia’s ratification of the Nagoya Protocol also makes access and benefit-sharing a board-level issue when genetic resources or associated traditional knowledge are involved. Do not ship material merely because a courier, importer, or overseas laboratory accepts it.

Foreign scientists create a parallel permission track. BRIN’s 2026 guidance continues to refer to ethics clearance, a Surat Izin Penelitian, and immigration controls in foreign-research governance. Determine whether each individual is a visiting foreign researcher, a PT PMA employee, a director performing executive duties, or a short-term specialist; research permission, employment authorization, and immigration status answer different legal questions and should not be treated as interchangeable.

Qualify the laboratory site and operating safeguards

A lease is usable only if the premises support the licensed activity and the risk controls. Screen zoning and spatial conformity, permitted building use, PBG and SLF status, power and backup capacity, water, drainage, ventilation, cold storage, chemical storage, access control, emergency systems, effluent, and biological or hazardous waste routes. The OSS basic-requirements framework separates spatial, marine-spatial, environmental, and building requirements; which ones apply depends on the land, water-space use, facility, and impact profile.

Translate protocols into rooms and controls before fit-out. The design basis should identify containment level, clean and dirty flows, sample receipt, quarantine where relevant, sterilization, controlled freezers, chain of custody, calibration, inventory, incident response, and validated disposal. A landlord’s permission for “office and laboratory” does not prove that chemical storage, wet laboratory drainage, live organism holding, or a pilot bioreactor is acceptable.

Genetic engineering changes the assessment. Indonesia’s Government Regulation 21 of 2005 on biosafety of genetically engineered products establishes a biosafety framework; later sector rules and the intended food, feed, environmental, or other release determine the assessment route. Laboratory research, confined trials, environmental release, and commercial product approval must be treated as separate milestones.

People complete the site. Define an Indonesian-resident operational lead, principal investigator responsibilities, biosafety or safety oversight, quality ownership, sample custodian, waste contractors, and emergency escalation. Foreign expertise may be essential, but it should sit within the correct work and research permissions and a documented transfer-of-knowledge plan where required.

Follow an evidence-led setup sequence

1. Freeze the phase-one operating model. State the first paid activity, research objectives, samples, methods, location, people, counterparties, and endpoint. Put later cultivation or manufacturing in a separately dated expansion phase.
2. Build a KBLI and ownership matrix. Compare 72104, 72105, 72103, technical testing, and endpoint codes. Record why each code is included or excluded and verify investment conditions current on the submission date.
3. Select the project address conditionally. Obtain preliminary spatial, environmental, building, landlord, utilities, waste, and biosafety evidence before making the lease unconditional or importing equipment.
4. Form and capitalize the PT PMA. Align the deed, shareholders, management, beneficial ownership, tax profile, bank evidence, and investment plan with the selected activities and locations.
5. Obtain the NIB and activity-based permissions. Complete the risk-based licence and fulfil the standards shown for each OSS project; do not read issuance of the NIB as permission to operate a laboratory whose required standard remains unverified.
6. Clear project overlays. Resolve research, ethics, foreign-personnel, access, sampling, marine-space, protected-species, quarantine, MTA, import/export, and biosafety requirements for the first protocol.
7. Commission under controlled conditions. Validate equipment, containment, SOPs, training, inventory, waste, emergency response, data integrity, and chain of custody before accepting live or irreplaceable material.
8. Run a product-change gate. Before selling a test, seed, ingredient, or finished product, confirm the additional KBLI, site, technical standard, product registration, labelling, quality, and distribution requirements.

The completion file should contain official corporate records, the final NIB and licence status for each project, spatial and building evidence, environmental decision, lease permissions, equipment and SOP registers, personnel permissions, collaboration and MTA documents, sample provenance, and the first protocol’s approvals. Screenshots without document numbers, scope, location, status, or validity should not be treated as closing evidence.

Budget for capital, permissions, and continuing compliance

There is no responsible single “marine biotechnology company cost.” A quote that combines capital, government charges, professional work, laboratory expenditure, and project permissions into one number hides both timing and risk. Ask for a staged budget with assumptions, exclusions, payment triggers, and official-fee evidence.

After launch, maintain corporate, tax, beneficial-ownership, employment, licence, environmental, waste, biosafety, sample, and project records. Medium and large enterprises, including PT PMA projects, have periodic LKPM reporting obligations. The operational register should connect each active KBLI and location to its investment realization, personnel, approvals, incidents, material movements, contracts, and products.

Build change control into the research organization. A new organism, collection area, foreign collaborator, recipient laboratory, genetic modification, larger pilot vessel, paid testing service, human-health claim, or commercial batch can alter the permit map. Require legal and scientific approval before procurement or protocol execution, rather than trying to regularize the change after material has moved.

Use a marine-biotech launch decision test

Proceed to incorporation when the founders can identify the first paid activity, defend the KBLI choice under KBLI 2025, confirm foreign-investment eligibility, fund the applicable PMA capital and project plan, and shortlist a site that can meet the real laboratory controls. Incorporation can run alongside conditional site and project due diligence, but it should not precede a basic decision on whether the business is R&D, testing, cultivation, manufacturing, or a staged combination.

Do not start field collection, receive sensitive material, bring a foreign researcher into an operational role, export a sample, conduct a regulated trial, or sell a product until the corresponding permission and evidence are active. Pause the project if provenance is unclear, a partner cannot grant transfer rights, the lease does not support the wet-lab design, the endpoint has no product pathway, or the investment model depends on treating paid-up capital as a fee that can immediately be withdrawn.

The company is launch-ready only when four records agree: the corporate and OSS record describes the activity; the site and people support it; the sample-and-research file authorizes the first protocol; and the product gate prevents experimental work from drifting into unlicensed supply. That alignment is the practical foundation for protecting the science, the investment, and access to Indonesian marine biodiversity.